


BRAND BOOK

 **Nihon Medi-Physics Co., Ltd.**

[Head office]
3-4-10 Shinsuna, Koto-ku
Tokyo 136-0075
Tel: 03-5634-7006
URL <http://www.nmp.co.jp/>

f o r t h e h a p p i n e s s

Meaning of the corporate name




“Medicine” and “Physics”,
the words comprising our corporate name,
are merged into the field of “Nuclear Medicine”,
in which our company operates.


Nuclear medicine is the advanced technology
applying the features of radioactivity to medical care.

Pharmaceuticals containing traces of radioisotopes (RI)
are used for diagnostic imaging, and tiny particles called seeds
emitting weak radiation is implanted into the body to treat cancer.

Our hope is to achieve wider awareness
of the value of “Nuclear Medicine” and to deliver better health
to as many patients as possible through our products.



Features of our business




Early detection of disease

is the advantage of diagnosis by nuclear medicine.


A disease can be discovered earlier by detecting a slight change
in physical functions such as blood flow or metabolism
shown on the image before the change of shape appears.

Early detection is especially important for serious diseases
such as cancer, cerebrovascular disease, and heart disease.


This examination method is considered to be
less-invasive and patient-friendly.




Business Fields




Based on its extensive knowledge and experience accumulated in the field of diagnostic nuclear medicine, Nihon Medi-Physics is also taking on a challenge in the development of technology and products in therapeutic field as well. With the medical device called a radioactive seed used in brachytherapy for prostate cancer, and radiopharmaceuticals mitigating the pain caused by bone metastasis of cancer, we will continue to contribute to human health by providing the values of nuclear medicine from the aspects of both “diagnosis” and “therapy”.



Social commitment




The radiopharmaceuticals used for diagnostic nuclear medicine are characterized by extremely short half-lives (the time required for the amount of radioactivity to reduce by half). Thus, the influence of the radioactivity on the human body is remarkably low, which is why it is considered to be highly safe technology. As a supplier providing radiopharmaceuticals to medical sites, we are aiming to gain wider confidence from society by giving priority to safety overall, not to mention the strict control of radiation in the production process.





Influence of radiation in nuclear medicine procedure

* The numerical value is quoted from “Nuclear Medicine Q&A” by Japan Radioisotope Association.



Foreseeing the needs of 10 to 15 years into the future is necessary for the development of pharmaceuticals. It is required to seek technical seeds (solutions) to satisfy these needs, while watching the future trends in medical care. By utilizing the know-how accumulated in diagnostic nuclear medicine, Nihon Medi-Physics will respond to unmet medical needs to achieve "our own" innovation in the field, including molecular imaging, where information within the body is imaged at a molecular level.



In 1973, Nihon Medi-Physics was established to achieve domestic production of radiopharmaceuticals, which had up to then been imported. The next year, the company commenced operation of Japan's first cyclotron for commercial use to distribute radiopharmaceuticals for SPECT procedure. In 2005, the company was the first in Japan to enter the PET diagnostic distribution field, and in the therapy field, the company released a medical device for use in brachytherapy for prostate cancer, also for the first time in Japan, in 2003. Our efforts have achieved many "firsts" in Japan. As a leading company in the field of nuclear medicine in Japan, we will dare to challenge and overcome future medical problems with the frontier spirit inherited from the time of our inauguration.

1973 START